DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "Asia-Pacific PDX Models Market - Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Asia-Pacific PDX models market is estimated to grow with a healthy CAGR in the forecast period 2018 to 2025.

Prominent factors driving the growth of this market consist of rising number of pharmaceutical R&D activities in cancer research, advantages offered by PDX models offer compared with the classic approach, rising need for personalized medicine and increasing support for cancer research activities from government and non-government organization.

The Asia Pacific PDX models market is segmented based on type into two notable segments; mice models and rat models. In 2018, mice models segment is valued to rule with the highest market share 2025.

The Asia Pacific PDX models market is segmented in tumor type categories into six notable segments; respiratory tumor models, urological tumor models, gastrointestinal tumor models, hematological tumor models, gynecological tumor models and others. In 2018, respiratory tumor models segment is valued to rule with the highest market shares by 2025, rising at the highest CAGR.

The Asia Pacific PDX models market is segmented in application into preclinical drug development and oncology research and biomarker analysis. In 2018, preclinical drug development and oncology research segment is valued to rule with highest market shares and rising at the highest CAGR.

The Asia Pacific PDX models market is segmented in end user into contract research organization (CRO), academic and research institutions and pharmaceutical and biotechnology companies. In 2018, contract research organization (CRO) segment is valued to rule with highest market shares and rising at the highest CAGR.

Market Dynamics

Drivers

Rising Number of Pharmaceutical R&D Activities in Cancer Research PDX Models Offer Advantages as Compared with the Classic Approach Rising Need for Personalized Medicine Increasing Support for Cancer Research Activities from Government & Non-Government Organization

Restraints

High Cost of PDX Models Strict Regulation with Respect to the Utilization of Animal Models in Cancer Research

Opportunities

Increasing Demand for Humanized PDX Models

Challenges

Limitations of PDX Models

Companies Profiled

Crown Bioscience Inc. The Jackson Laboratory Champion Oncology Inc. Charles River Oncodesign Wuxi AppTec Horizon Discovery Group PLC Pharmatest Services Hera Biolabs EPO Berlin-Buch GmbH Xentech Urolead Creative Animodel EUROPDX MI Bioresearch Inc. Aragen Bioscience

For more information about this report visit https://www.researchandmarkets.com/research/647q8g/asiapacific_pdx?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005356/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery

KEYWORD: ASIA PACIFIC

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 07:49 AM/DISC: 08/23/2018 07:49 AM

http://www.businesswire.com/news/home/20180823005356/en